Navigation Links
Neurobiological Technologies Announces Intent to File Form 25 to Delist Common Stock From the NASDAQ Capital Market
Date:10/19/2009

EMERYVILLE, Calif., Oct. 19 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (Nasdaq: NTII) ("NTI") announced today it has submitted written notice to the NASDAQ Stock Market LLC ("NASDAQ") that NTI intends to file a Form 25 with the Securities and Exchange Commission ("SEC") on or about October 28, 2009 to effect the voluntary delisting of its common stock from NASDAQ, if NTI's stockholders approve the dissolution of the company pursuant to a Plan of Complete Liquidation and Dissolution at the special meeting of stockholders planned for Tuesday, October 27, 2009.

Details of NTI's plans to pay an extraordinary dividend, delist its common stock from the Nasdaq Capital Market, discontinue recording transfers of stock, cease its reporting obligations under the Securities Exchange Act of 1934, as amended, and distribute its net cash to stockholders can be found in a definitive proxy statement filed with the SEC on September 22, 2009.

About Neurobiological Technologies, Inc.

Neurobiological Technologies, Inc. is a biopharmaceutical company historically focused on developing investigational drugs for central nervous system conditions.

SOURCE Neurobiological Technologies, Inc.


'/>"/>
SOURCE Neurobiological Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Neurobiological Technologies Receives Nasdaq Closing Bid Price Notification
2. Neurobiological Technologies Announces Termination of its License and Cooperation Agreement with Merz and Childrens Medical Center
3. Neurobiological Technologies Announces Hiring of Advisor to Seek Sale of Company
4. Neurobiological Technologies Reports Second Quarter Fiscal 2009 Financial Results
5. Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine
6. Neurobiological Technologies Announces Suspension of Viprinex Development
7. Neurobiological Technologies Partner, Celtic Pharma, Provides Update on XERECEPT(R) Clinical Program and Planned Sale in 2009
8. Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financial Results
9. Neurobiological Technologies to Present at the Rodman & Renshaw 10th Annual Healthcare Conference in New York on November 10
10. Neurobiological Technologies Sets Date for First Quarter Financial Results
11. Neurobiological Technologies Reports Receipt of $2 Million Royalty Payment for Quarterly Sales of Memantine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Cancer experts from ... believe could be a new and helpful biomarker for malignant pleural mesothelioma. Surviving ... to read it now. , Biomarkers are components in the blood, tissue ...
(Date:6/27/2016)... ... June 27, 2016 , ... Newly ... technologies, services and solutions to the healthcare market. The company's primary focus is ... manufacturing, sales and marketing strategies that are necessary to help companies efficiently bring ...
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... on a range of subjects including policies, debt and investment ... Speaking at a lecture to the Canadian Economics ... the country,s inflation target, which is set by both the ... "In certain areas there needs to be frequent ... not sit down and address strategy together?" He ...
Breaking Biology Technology:
(Date:6/2/2016)... 2016   The Weather Company , an IBM Business ... industry-first capability in which consumers will be able to interact ... questions via voice or text and receive relevant information about ... Marketers have long sought an advertising solution that can ... personal, relevant and valuable; and can scale across millions of ...
(Date:5/16/2016)... May 16, 2016   EyeLock LLC , a ... the opening of an IoT Center of Excellence in ... expand the development of embedded iris biometric applications. ... of convenience and security with unmatched biometric accuracy, making ... aside from DNA. EyeLock,s platform uses video technology to ...
(Date:4/28/2016)... GOTHENBURG, Sweden , April 28, 2016 ... 1,491.2 M (139.9), up 966% compared with the first quarter of ... Operating profit totaled SEK 589.1 M (loss: 18.8) and the operating ... SEK 7.12 (loss: 0.32) Cash flow from operations was ... , The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
Breaking Biology News(10 mins):